

BIG BAR RESOURCES CORPORATION

NEWS RELEASE

BIG BAR ANNOUNCES DEFINITIVE AGREEMENT WITH CVR GLOBAL, INC. AND PROPOSED CHANGE OF BUSINESS

November 16, 2015 – Vancouver, British Columbia (**NEX Board of TSX-V: BBR.H**) Big Bar Resources Corporation ("**Big Bar**" or the "**Company**"), further to its previous news release, is pleased to announced that it has entered into a definitive agreement with CVR Global, Inc. ("**CVR**") for the acquisition (the "**Transaction**") of patents (collectively, the "**Patents**") relating to a diagnostic device developed by CVR which is designed to detect and measure carotid arterial stenosis (the "**Device**").

CVR is a Michigan incorporated private company dedicated to the commercialization of a proprietary sub-sonic technology for the medical industry.

Terms of the Transaction

As previously announced, Big Bar will acquire the Patents through the issuance of an aggregate of 7,000,000 of its common shares (the "**Consideration Shares**") to CVR at a price per Consideration Share that is anticipated to be equal to the price per unit to be issued in the private placement financing that the Company intends to complete with the Transaction, as described further below in this News Release.

Upon closing of the Transaction, CVR and Big Bar will form a joint venture (the "**Joint Venture**") pursuant to which Big Bar will contribute the Patents and working capital, and CVR will contribute certain additional patents and intellectual property, the Device, as well as management know-how and marketing expertise, for an initial equal equity interest by both parties in the Joint Venture.

Financing

Concurrently with, or as soon as practicable following the closing of the Transaction, the Company intends to complete a private placement for gross proceeds of \$1.5 million (the "**Financing**"), which is expected to consist of units with each unit comprised of one common share and one-half of one common share purchase warrant at a price of \$0.25 per unit, or such other price per unit determined by Big Bar management in compliance with TSX Venture Exchange (the "**Exchange**") pricing regulations. Each whole share purchase warrant will be exercisable to acquire one common share of the Company at a price of \$0.40 per share for a period of twelve months following the Closing Date. The Financing may be brokered or non-brokered and Agent's commissions and/or finder's fees in cash or securities may be payable in connection with the Financing subject to

compliance with Exchange (the "**Exchange**") policies. Proceeds from the Financing are expected to be used as follows:

Regulatory Consulting	Preparation of US Food & Drug Administration DA 510(K) submission and regulatory compliance	\$ 187,500.00
IP	Filing of additional provisional patent applications	87,500.00
Clinical Trials	Undertaking of clinical trials	250,000.00
R&D	Lab Equipment/Software	187,500.00
Manufacturing	Order complete CSS devices for clinical trials	687,500.00
	Finalize pivotal trial device	
	Moulding and plastic tooling of touch panel PC and sensor array	
Marketing & Sales	Marketing Literature/PR/Tradeshows/Seminars	100,000.00
		\$ 1,500,000.00

All securities issued pursuant to the Financing will be subject to a hold period as required under applicable securities legislation.

Change of Business

Completion of the Transaction as contemplated would constitute a Change of Business in accordance with Exchange Policy 5.2 *Changes of Business and Reverse Takeovers* ("**Policy 5.2**") as the Company's current business is the exploration of minerals. As a result the Transaction is subject to Exchange acceptance and will also require approval of the shareholders of Big Bar.

Conditions

The Transaction is subject to a number of conditions including, but not limited to, arrangement of the Financing, delivery by CVR of a satisfactory valuation as to the value of the Patents, completion of due diligence reviews by the parties and approval by each of the Big Bar and CVR boards of directors.

Management Changes

Under the terms of the agreement, certain management changes are intended to occur concurrently with the closing of the Transaction pursuant to which two nominees of CVR will be appointed to the Company's board of directors and the officers of CVR will replace the Company's current officers, with the exception of Big Bar's CFO, Erwin Wong, who will remain in such position. Big Bar will have two representatives on the board of directors of CVR, as well as being entitled to appoint the CVR Chief Financial Officer.

Other Information and Updates

In accordance with Exchange policy, the Company's shares are halted from trading and will remain halted until such time as determined by the Exchange, which, depending on the policies of the

Exchange, may not occur until the completion of the Transaction.

The Company will provide further details in respect of the Transaction, in due course, by way of news releases.

ON BEHALF OF THE BOARD:
(signed) "Ron Birch"
President & Director

For further information contact:
Ron Birch, President and Director
Telephone: 1-800-910-7711

This news release contains statements about the Company's expectations regarding the completion of the Transaction that are forward-looking in nature and, as a result, are subject to certain risks and uncertainties. Although the Company believes that the expectations reflected in these forward-looking statements are reasonable, undue reliance should not be placed on them as actual results may differ materially from the forward-looking statements and there can be no assurance that such expectations will prove to be correct. Factors that could cause the actual results to differ materially from those in forward-looking statements include failure to complete the Transaction for any reason whatsoever, including failure to obtain Exchange acceptance or shareholder approval therefor. The forward-looking statements contained in this news release are made as of the date hereof, and the Company undertakes no obligation to update publicly or revise any forward-looking statements or information, whether as a result of new information, future events or otherwise, except as required by applicable securities laws. The forward-looking statements contained in this news release are expressly qualified by this cautionary statement.

This news release does not constitute and the subject matter hereof is not, an offer for sale or a solicitation of an offer to buy, in the United States or to any "U.S. Person" (as such term is defined in Regulation S under the U.S. Securities Act of 1933, as amended (the "1933 Act")) of any equity or other securities of the Corporation. The securities of the Corporation have not been registered under the 1933 Act and may not be offered or sold in the United States (or to a U.S. Person) absent registration under the 1933 Act or an applicable exemption from the registration requirements of the 1933 Act.

Completion of the Transaction is subject to a number of conditions, including Exchange acceptance and shareholder approval. The Transaction cannot close until the required shareholder approval is obtained. There can be no assurance that the Transaction will be completed as proposed or at all.

Investors are cautioned that, except as disclosed in the management information circular to be prepared in connection with the Transaction, any information released or received with respect to the Transaction may not be accurate or complete and should not be relied upon. Trading in the securities of the Company should be considered highly speculative.

The Exchange has in no way passed upon the merits of the Transaction and has neither approved nor disapproved the contents of this news release.